As one of the most common urological malignancies, the therapy for ccRCC has made outstanding achievements, including the development and application of various targeted therapeutic agents, such as VEGF inhibitors, mTOR inhibitors, and immune checkpoint inhibitors, in recent years [31]. Here, MTOR is linked to nonpapillary renal cell carcinoma.